Pediatrics & Health Research Open Access

  • ISSN: 2574-2817
  • Journal h-index: 3
  • Journal CiteScore: 0.36
  • Journal Impact Factor: 0.77
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Twice daily dosing of indomethacin is more effective in PDA closure compared to daily Indomethacin or Ibuprofen

14th World Congress on General Pediatrics & Adolescent medicine
September 25-27, 2017 Chicago, USA

Maliha Shareef

Loyola University, USA

Posters & Accepted Abstracts: Ped Health Res

Abstract:

Objective: To determine whether ibuprofen or indomethacin, and which dosing interval of indomethacin, is most effective in achieving closure of a patent ductus arteriosus (PDA), and if there is a difference in complication rates. Study Design: In this study, 257 infants were retrospectively reviewed and divided into 1 of 3 treatment groups: daily ibuprofen, daily and twice daily indomethacin. One course of treatment was given over 3 days. Chi-squared and Wilcoxon tests were used. Results: Twice daily indomethacin, ibuprofen, and daily indomethacin had PDA closure rates of 76%, 60% and 57% respectively. When compared to both ibuprofen and daily indomethacin, twice daily indomethacin use resulted in a higher closure rate (p=0.019, p=0.012 respectively) and this comparison held true when controlling for gestational age. Ibuprofen and daily indomethacin had similar closure rates (p=0.661). An increase in NEC was seen in the daily indomethacin group as compared to the ibuprofen group (p=0.194). Otherwise there was no significant difference in gastrointestinal perforation, bronchopulmonary dysplasia, intraventricular hemorrhage, or mortality. Conclusion: A 6 dose course of twice daily dosing of indomethacin is significantly more effective at achieving PDA closure compared to a 3-dose course of daily dosing of either indomethacin or ibuprofen, with an increase in NEC rates seen in twice daily indomethacin.